Year All202520242023202220212020201920182017 Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights Mar 22, 2023 Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference Mar 01, 2023 Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 Feb 16, 2023 Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023 Feb 06, 2023 Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress Jan 09, 2023 Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency Dec 05, 2022 Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference Dec 01, 2022 Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates Nov 10, 2022 Inozyme Pharma to Participate in Upcoming Investor Conferences Nov 07, 2022 Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial Nov 03, 2022
Year All202520242023202220212020201920182017 Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights Mar 22, 2023 Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference Mar 01, 2023 Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 Feb 16, 2023 Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023 Feb 06, 2023 Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress Jan 09, 2023 Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency Dec 05, 2022 Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference Dec 01, 2022 Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates Nov 10, 2022 Inozyme Pharma to Participate in Upcoming Investor Conferences Nov 07, 2022 Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial Nov 03, 2022
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights Mar 22, 2023
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency Dec 05, 2022
Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates Nov 10, 2022
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial Nov 03, 2022